This product is a box of 10 vials.
PT-141 is a new innovative peptide hormone treatment that works for both men and women to improve sexual function. PT-141 is an effective and efficient treatment for both erectile dysfunction and increased libido in men and improves female sexual arousal disorder in women. PT 141 works directly through the nervous system to increase arousal, desire, and satisfaction with sex. PT 141 peptide gives you the desire and motivation along with the ability to increase blood flow to the penis or vagina and clitoris, returning the intimacy and passion to your relationship. PT 141 addresses those issues to help resolve sexual difficulties.
The Dopamine Studies
What Is PT-141Â ?
PT-141, also called Bremelanotide (its generic clinical name), is a strongly modified man-made version of alpha-melanocyte-stimulating hormone. It has been tested in clinical trials as a treatment for both male and female hypoactive sexual desire disorder, as well as for acute bleeding. PT-141 activates the melanocortin-4 and melanocortin-1 receptors. Studies show it promotes sexual arousal and boosts the immune system.
Sequence: Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)
Molecular Formula: C50H68N14O10
Molecular Weight: 1025.182 g/mol
PubChem CID: 9941379
CAS Number: 189691-06-3
Sexual Arousal
PT-141 is unique because it activates the MC-4R, which is known to create sexual arousal in the central nervous system and affect sexual behavior. Studies in mice have shown that activating MC-4R leads to sexual arousal and more mating in both males and females. Since PT-141 works through a different process than drugs like Viagra, it may help treat sexual arousal problems in men and women caused by things other than poor blood flow to the genitals.
A study of men with erectile dysfunction (ED) who did not respond to sildenafil (Viagra) found that about one third got a strong enough erection for sex when using PT-141 given through a nasal spray. The trial also showed a clear link between dose and response, confirming PT-141 works in some cases. This suggests PT-141 could help fix ED where sildenafil fails and may reveal central causes of low sexual desire.
PT-141 was pulled from clinical trials before getting approval for women with HSDD. This happened even though the drug increased satisfying sexual events per month and lowered female sexual distress scores in a meaningful way, with no major side effects. Many experts who treat female sexual dysfunction (FSD) were upset that the peptide was not moved forward despite good results. They point to unclear trial goals for FSD and cultural biases against women's sexual health as the main barriers blocking approval of needed treatments. They hope more focus will come to the issue and that the FDA will create clearer rules for testing treatments like PT-141 that could help. These experts also wished pharmacological options were tested with other proven ways to treat sexual dysfunction, as they think the mix could work better together. They see peptides like PT-141 as useful for breaking early barriers and starting psychological treatments.
In 2017, partly due to complaints about stopping earlier trials, Phase II Reconnect trials started using under-the-skin injections of PT-141 for FSD. The newest version of PT-141, now called Vyleesi, has been available in the United States since 2019. It is legal to use PT-141 off-label to treat both male and female sexual dysfunction. These newer trials used the updated trial goals that FSD experts have pushed for to help get such treatments approved.
Hemorrhage
In 2009, PT-141 was slightly changed and tested as a possible treatment for hemorrhagic shock. Since PT-141 binds to both MC-1R and MC-4R, it reduces tissue damage from poor blood flow during low-blood-volume shock. When given through a vein, the drug causes few side effects. It was last in phase IIb trials. This changed version of PT-141 is called PL-6983.
Infection
In a rat model of a certain fungal infection, the MC-1R showed key anti-fungal and anti-inflammatory effects. This matters because current anti-fungal drugs have limited ways of working and can cause serious side effects in some patients. A new option for treating fungal infections could greatly lower illness and death rates, especially in people with weak immune systems.
Cancer
The MC-1R receptor plays a big role in DNA repair paths, making it interesting for cancer treatment and prevention. Studies show people with changes in MC-1R have higher risk for basal cell and squamous cell skin cancers. Modified PT-141 might fix issues from these changes and help prevent or treat these cancers.
Curious about PT-141 (Bremelanotide)?
Join our Facebook group to engage directly with thousands of others who use this product, and follow our Facebook/IG pages for hot updates and product announcements!
